As a company, Bayer is a part of society and of public life. Ongoing and systematic dialogue with our stakeholders is therefore particularly important to us. Their expectations and viewpoints affect public acceptance of Bayer and thus our commercial success.
Stakeholder dialogue helps us to recognize important trends and developments in society and our markets at an early stage and take this information into account when designing our business. The integration of various stakeholder groups is planned within the scope of our stakeholder engagement process. This process also includes monitoring the results of individual dialogue measures. In strategic decision-making processes such as investment projects and launches of new products, Bayer approaches key social and political players right from the start of a new project to canvass their support. The open dialogue makes it possible to identify opportunities and risks early on. This process is in line with our Stakeholder Engagement Directive and is supplemented by an internal information platform.
We fundamentally distinguish four stakeholder groups with which we engage in various dialogue formats.
Bayer is an active member of, or holds leadership positions in, numerous associations and their committees. Examples include the Federation of German Industries (BDI; Executive Committee), the German Chemical Industry Association (VCI; Vice Presidency) and the German Equities Institute (DAI; Executive Committee and Board). Bayer also provides the Chairman of the Administration Board of econsense, the Forum for Sustainable Development of German Business.
Our divisions are active members of their respective industry associations and committees. For example, Pharmaceuticals is represented on the boards of both the European (EFPIA) and the U.S. (PhRMA) pharmaceutical industry associations. In addition, Bayer is on the board of the Association of Research-Oriented Pharmaceutical Manufacturers (VfA) and is an active member of the German Medicines Manufacturers’ Association (BAH). Consumer Health has leadership functions in relevant industrial and trade associations. The member of the Bayer Board of Management responsible for Consumer Health is on the Board of Directors of the World Self-Medication Industry (WSMI). Divisional representatives are furthermore on the boards of regional self-medication associations, such as the Association of the European Self-Medication Industry (AESGP) and Cosmetics Europe (CE). The Crop Science Division is represented, for example, on the Board of Administration of CropLife International (CLI) – an international association for crop protection and plant biotechnology – as well as on the European Crop Protection Association (ECPA) and the Executive Committee of the German Association of the Agricultural Industry (IVA). In addition, Crop Science is represented on the Board of Administration and the Scientific Committee of the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC).
Crop Science is furthermore a supporter of the International Food Information Council (IFIC) and a member of the Biotech Innovation Organization (BIO), the world’s largest biotech trade association. Moreover, Crop Science holds memberships in the North American Council for Biotechnology Information (CBI), the European Seed Association (ESA), the biotech lobbying organization EuropaBio and the International Seed Federation (ISF), which represents the interests of the seed industry on a global level. Crop Science is likewise on the board of the German Association of Biotechnology Industries (DIB) and a member of the German Plant Breeders’ Association (BDP).
Animal Health is represented on the boards of many German and international associations, including Health for Animals.